Literature DB >> 29439959

In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions.

Mika Murata1,2, Kosuke Kosai3, Shunsuke Yamauchi1, Daisuke Sasaki1, Norihito Kaku2, Naoki Uno2, Yoshitomo Morinaga2, Hiroo Hasegawa1, Taiga Miyazaki4, Koichi Izumikawa4, Hiroshi Mukae5, Katsunori Yanagihara2.   

Abstract

Lascufloxacin showed potent activity against Streptococcus pneumoniae with a GyrA or ParC mutation (first-step mutant). The frequency of selecting resistant strains tended to be lower for lascufloxacin than for levofloxacin and garenoxacin after drug exposure in first-step mutants but was similar in the comparison between lascufloxacin and moxifloxacin. The increase in MIC was smaller for lascufloxacin than for levofloxacin, garenoxacin, and moxifloxacin when clinical strains with only ParC mutations were exposed to the corresponding drug.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Streptococcus pneumoniae; fluoroquinolone resistance; lascufloxacin

Mesh：

Substances：

Year:  2018        PMID： 29439959      PMCID： PMC5913943          DOI： 10.1128/AAC.01971-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.

Authors:  Xinying Li; Xilin Zhao; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.

Authors:  H Fukuda; R Kishii; M Takei; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).

Authors:  Todd A Davies; Y Cheung Yee; Raul Goldschmidt; Karen Bush; Daniel F Sahm; Alan Evangelista
Journal:  J Antimicrob Chemother       Date:  2006-01-23       Impact factor: 5.790

4.  Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation.

Authors:  M de Cueto; J M Rodríguez; M J Soriano; L López-Cerero; J Venero; A Pascual
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

5.  Genetic diagnosis of community-acquired MRSA: a multiplex real-time PCR method for Staphylococcal cassette chromosome mec typing and detecting toxin genes.

Authors:  Maiko Motoshima; Katsunori Yanagihara; Yoshitomo Morinaga; Junichi Matsuda; Kazuyuki Sugahara; Yasuaki Yamada; Shigeru Kohno; Shimeru Kamihira
Journal:  Tohoku J Exp Med       Date:  2010-02       Impact factor: 1.848

6.  In Vitro Activities and Spectrum of the Novel Fluoroquinolone Lascufloxacin (KRP-AM1977).

Authors:  Ryuta Kishii; Yuko Yamaguchi; Masaya Takei
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

7.  Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

Authors:  Angela B Brueggemann; Stacy L Coffman; Paul Rhomberg; Holly Huynh; Laurel Almer; Angela Nilius; Robert Flamm; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

8.  In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.

Authors:  Kazuko Yamamoto; Katsunori Yanagihara; Kazuyuki Sugahara; Yoshifumi Imamura; Masafumi Seki; Koichi Izumikawa; Hiroshi Kakeya; Yoshihiro Yamamoto; Yoichi Hirakata; Shimeru Kamihira; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

9.  Molecular characterization of quinolone-insensitive Streptococcus pneumoniae isolates from Japanese patients.

Authors:  Nobuko Araki; Katsunori Yanagihara; Yoko Matsukawa; Yosuke Harada; Yohei Migiyama; Kentaro Nagaoka; Koichi Yamada; Yoshitomo Morinaga; Hiroo Hasegawa; Shigeru Kohno; Shimeru Kamihira
Journal:  J Infect Chemother       Date:  2012-08-22       Impact factor: 2.211

10.  Clinically relevant fluoroquinolone resistance due to constitutive overexpression of the PatAB ABC transporter in Streptococcus pneumoniae is conferred by disruption of a transcriptional attenuator.

Authors:  Alison J Baylay; Laura J V Piddock
Journal:  J Antimicrob Chemother       Date:  2014-11-18       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.